/
CLNN
$6.34+$0.28 (+4.54%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$77.4M
13M shares
52-week range
$3.25 – $13.50
30% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
4.80%
Moderate
Price (6 mo)
Loading chart…
Change$-218.47
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $206.0K | $723.0K | $473.0K | $654.0K | $342.0K | $200.0K |
| Cost of revenue | $0 | $900.0K | $65.0K | $289.0K | $26.0K | $121.0K | $70.0K | $43.0K |
| Gross profit | $0 | −$900.0K | $141.0K | $434.0K | $447.0K | $533.0K | $272.0K | $157.0K |
| Gross margin | — | — | 68.4% | 60.0% | 94.5% | 81.5% | 79.5% | 78.5% |
| R&D | $6.6M | $8.8M | $15.2M | $28.4M | $31.9M | $26.7M | $20.1M | $14.0M |
| Operating income | −$323.9K | −$16.3M | −$20.2M | −$50.0M | −$48.4M | −$40.5M | −$33.1M | −$23.1M |
| EBITDA | −$8.5M | −$15.2M | −$17.0M | −$8.3M | −$25.6M | −$43.2M | −$33.7M | −$22.0M |
| Net income | −$277.3K | −$16.2M | −$19.3M | −$9.7M | −$29.9M | −$49.5M | −$39.4M | −$26.2M |
| Net margin | — | — | -9357.8% | -1347.2% | -6325.2% | -7569.4% | -11520.5% | -13086.5% |
| EPS (diluted) | -0.09 | -4.69 | -5.51 | -3.16 | -4.69 | -9.43 | -5.67 | -2.65 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $207400 | $-1.79 | $-1.90–$-1.67 | 3 |
| 2027 | $24M | $-1.47 | $-1.73–$-1.21 | 3 |
| 2028 | $166M | $2.11 | $-0.62–$5.89 | 5 |
| 2029 | $340M | $6.04 | $-1.65–$18.46 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Clene Inc. Common Stock
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
www.clene.com- Employees
- 79
- IPO / List date
- Dec 31, 2020
- HQ
- SALT LAKE CITY, UT
Held by traders on TradeandTell
No one on the platform currently holds CLNN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 30,440 | $183.4K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-07-11 | 1-for-20reverse |
Recent trades on TradeandTell
No one on the platform has traded CLNN yet.
